Related Experiment Videos
Platelet function in patients with obstructive sleep apnoea syndrome.
B M Sanner1, M Konermann, M Tepel
1Dept. of Medicine I, Ruhr University Bochum, Marienhospital Herne, Germany.
The European Respiratory Journal
|December 6, 2000
Summary
Obstructive sleep apnoea syndrome (OSAS) increases cardiovascular risk by affecting platelet function. Continuous positive airway pressure (CPAP) therapy significantly reduces this platelet hyperaggregability, improving cardiovascular health.
Area of Science:
- Cardiology
- Sleep Medicine
- Hematology
Background:
- Obstructive sleep apnoea syndrome (OSAS) is linked to increased cardiovascular morbidity, including myocardial infarction and stroke.
- Platelets are crucial in acute cardiovascular events, but OSAS's impact on platelet function remains unclear.
Purpose of the Study:
- To investigate the influence of OSAS on platelet aggregability.
- To assess the long-term effects of continuous positive airway pressure (CPAP) therapy on platelet function in OSAS patients.
Main Methods:
- Platelet aggregability to various agonists (epinephrine, collagen, arachidonic acid, ADP) was measured in 17 male OSAS patients and 15 male controls at different times.
- Platelet function was re-evaluated after 6 months of CPAP therapy in OSAS patients.
Main Results:
- Untreated OSAS patients showed a slight overnight increase in epinephrine-induced platelet aggregation, unlike controls and treated patients.
- CPAP therapy significantly reduced platelet aggregability at 24:00 h and 06:00 h in OSAS patients (p<0.05 and p=0.01, respectively).
- Platelet aggregability in controls during sleep mirrored that of OSAS patients undergoing CPAP therapy.
Conclusions:
- OSAS contributes to platelet dysfunction and increased cardiovascular risk.
- Long-term CPAP therapy can effectively reduce platelet hyperaggregability in OSAS patients.